Scarica l'app Stockscreener
4.99
3.48%
-0.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$5.17
Aprire:
$5
Volume 24 ore:
46,934
Relative Volume:
0.12
Capitalizzazione di mercato:
$40.81M
Reddito:
$120.77M
Utile/perdita netta:
$32.69M
Rapporto P/E:
1.7121
EPS:
2.9146
Flusso di cassa netto:
$-50.94M
1 W Prestazione:
+5.94%
1M Prestazione:
+1.63%
6M Prestazione:
-65.54%
1 anno Prestazione:
-18.60%
Intervallo 1D:
$4.87
$5.26
Intervallo di 1 settimana:
$4.30
$5.26
Portata 52W:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.99 | 40.81M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Atara Biotherapeutics, Inc. (ATRA) registers possible resale of 400K common shares tied to HCR warrant exercise - MSN
Securities Fraud Investigation Into Atara Biotherapeutics, Inc - natlawreview.com
ATRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - Lelezard
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - Sahm
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ROSEN Counsel Encourages Atara Biotherapeutics Investors to Act - National Today
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
ATRA Technical Analysis & Stock Price Forecast - Intellectia AI
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise - Yahoo Finance
Aug Sectors: Is Atara Biotherapeutics Inc being accumulated by smart moneyWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - The Norfolk Daily News
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Atara Biotherapeutics Faces Class Action Lawsuit - Intellectia AI
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors ... - Bluefield Daily Telegraph
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - marketscreener.com
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - GlobeNewswire Inc.
2026-04-01 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ATRA Stock Price, Quote & Chart | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
Did You Lose Money Investing in Atara Biotherapeutics, - GlobeNewswire
Pomerantz Law Firm Files Class Action Against Atara Biotherapeutics - National Today
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics Lawsuit - National Today
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in - GuruFocus
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atara Biotherapeutic - natlawreview.com
Atara Biotherapeutics | 10-K: FY2025 Annual Report - Moomoo
Class Action Filed Against Atara Biotherapeutics, Inc. (ATRA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - globenewswire.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Bioth - GuruFocus
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - ChartMill
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action - ChartMill
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
ATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara ... - Bluefield Daily Telegraph
ATRA Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atara Biotherapeutics Inc Azioni (ATRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Mar 02 '26 |
Sale |
5.08 |
2,104 |
10,691 |
31,750 |
| Nguyen AnhCo | President and CEO |
Mar 02 '26 |
Sale |
5.09 |
2,996 |
15,237 |
61,978 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):